3/10/2022

speaker
Ashley
Conference Operator

Good day and thank you for standing by. Welcome to Q4 2021 Solaris Pharmaceuticals earnings webcast and conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to Jason Randall of Cibaran Strategic Advisors. Please go ahead.

speaker
Jason Randall
Cibaran Strategic Advisors

Good afternoon, and thank you for joining Solaris Pharmaceuticals' 2021 Fourth Quarter and Full Year Financial and Corporate Results Call. This afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months and full year ended December 31, 2021, which we encourage listeners to read. The press release can be found in the news section of SolarisPharma.com. Before beginning today's call, I would like to make the following statement. Today, we'll be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, the development and effectiveness of our investigational drug candidates, SecloDemsat, and SP3164. as well as our targeted protein degradation program, and expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements. Action results may differ materially due to our risks and uncertainties, including those detailed in the risk factors section of Solaris Pharmaceutical's annual report on Form 10-K for the year ended 2021, and subsequent quarterly reports on Form 10-Q which have been filed with the SEC, as well as in other filings we make with the SEC from time to time. Solaris Pharmaceuticals disclaims any obligation to update information containing these forward-looking statements, whether as a result of new information, future events, or otherwise. With us on today's call is David Arthur, Director and CEO of Solaris Pharmaceuticals, who provided an update on Solaris' corporate and clinical achievements during the fourth quarter and its vision for the future. And Mark Rosenblum, CFO, will review Solaris' fourth quarter financial results. With that, David, please go ahead.

speaker
David Arthur
Director and CEO, Solaris Pharmaceuticals

Thank you, Jason, and thank you to everyone dialing in to our conference call, particularly all of you joining us for the first time. Last year and recent weeks were an exciting time for Solaris, highlighted by the continuing progress developing CECLA DemStat and the expansion of our development pipeline. In January, we acquired a portfolio of assets from Duterex LLC, which included the drug candidate 3164, SP 3164, a related intellectual property portfolio, and the opportunity to develop additional cancer-fighting assets. This acquisition formed the basis of our new cancer drug development program focused on targeted protein degradation, a fast-growing field of cancer drug research. With this one transaction, Solaris has grown from a company with a single clinical program into a company with an internal pipeline consisting of multiple drug development programs built around two exciting approaches to cancer drug development, protein inhibition and protein degradation. This acquisition marks a significant step forward for Solaris and provides a bookend for what was a busy 2021 where in addition to advancing secludemstat, we completed financial transactions that strengthened our financial position, completed the dose escalation portion of our sarcoma trial, added two additional patient treatment groups to our sarcoma trial, added numerous clinical trial sites to enroll patients in our sarcoma trial, activated an investigator-initiated clinical trial in hematologic cancers at MD Anderson Cancer Center, our advanced solid tumor trial, which supported our sarcoma trial expansion and initiated a number of research collaborations. We believe 2021 was a successful year, but now I'd like to spend some time talking about the future. Our priorities for 2022 are clear. We believe that we are well-positioned, and I'd like to tell you what we plan to achieve both with seclidemstat and with SP3164. I think you'll understand why we at Solaris are excited about the future. For a long time, I've talked to you almost exclusively about seclidemstat. Seclidemstat, as you know, is a reversible protein inhibitor that targets LSD1, an enzyme that is overexpressed in many types of cancer, and is a promising target for anti-cancer drug therapies. As I've discussed in previous calls, secludemstat is currently the subject of two separate Phase I-II clinical trials. The first trial is exploring its potential as a monotherapy treatment in two groups of sarcoma patients, myxoid liposarcoma and FEP-rearranged sarcomas, and also exploring its potential in chemotherapy combination treatment in a third type of sarcoma, Ewing sarcoma. The second trial is exploring its potential in patients with two aggressive forms of hematologic or blood cancers. Ceclodemstac continues to advance in the clinic with patients enrolling across both clinical trials. And as we've discussed previously, we are looking forward to providing updates later this year. With that said, I'd like to take the opportunity to discuss our recent acquisition involving SP-3164 and how this acquisition adds additional potential above and beyond our protein inhibition program led by Sekla Demstat. As mentioned earlier, the assets acquired through our transaction with Duterex form the basis of our new cancer drug development program. This program is focused on targeted protein degradation fast-growing field of cancer drug research. Targeted protein degradation involves harnessing the body's natural degradation system to selectively target and eliminate disease-causing proteins, and by doing so, stop the development and progression of cancer. This field of research has already transformed the treatment of cancer with products like BMS cell genes Revloid and Pomelast, both protein degraders, which combined for over $15 billion in global sales in 2020 and are indicated for treatment of cancers such as non-Hodgkin's lymphoma and multiple myeloma. We believe these early generation protein degraders are only the tip of the iceberg in the potential for protein degradation to deliver efficacious medicines that are able to overcome drug resistance and achieve a therapeutic effect with small quantities of drugs. Perhaps the most exciting is the potential to use targeted protein degradation to pursue medicines targeting cancer-promoting proteins that have historically been considered undruggable. Other pharmaceutical companies seem to share our vision, as demonstrated by recent deal-making around targeted protein degradation that reads like a who's who list of the biopharmaceutical industry. For example, last year Pfizer inked a drug development deal with Arvinas worth about $1 billion, Bayer acquired Vividium Therapeutics for $1.5 billion, and Novartis entered into a transaction with UK-based Dunab Therapeutics worth $1.3 billion. And just last month, Amgen completed a $500 million multi-year drug development deal with Plexium. From our viewpoint, it is apparent that these drug makers see value in targeted protein degradation given the commercial success of the first-generation molecular glues or protein degraders and the tremendous upside to developing new drugs targeting previously or historically undruggable targets. But beyond the financial allure and multibillion-dollar commercial market potential, we believe that targeted protein degradation represents an excellent strategic fit for salarius. We believe we can harness our existing scientific expertise in gene dysregulation and protein expression and our growing clinical infrastructure to efficiently advance 3164 into the clinic. Building on our optimism around 3164 is our belief that the asset will have a strong clinical safety profile and the potential to be superior from an efficacy perspective versus other comparable drugs. 3164 is an oral, small-molecule, cereblon-binding protein degrader, referred to as a molecular glue because it is designed to attract or bring disease-causing proteins into proximity with an enzyme that induces targeted protein degradation. Or in simpler terms, it eliminates the disease-causing proteins. 3164 was engineered by Duterex from a first-generation molecular glue, avatamide, using a unique process called deuterium-enabled switching, or DEX, V-E-C-S, to create a new novel molecular entity with the potential for increased efficacy and improved safety compared to avatamide. Why is this important? This is important because Avatamide, also known as CC122 or Celgene 122, was widely studied in over 400 patients across 10 clinical trials. It showed a promising safety profile, good pharmacokinetics, and importantly, anti-tumor activity across several cancer types with what we believe is strong data in lymphomas. So we believe that the considerable amount of validated, published data produced in the development of Avatamide will significantly help us guide 3164's development. But let's remember that 3164 is an entirely new molecular entity with its own unique and improved characteristic and its own composition of matter patent. In fact, in preclinical animal studies, 3164 showed improved efficacy and increased anti-tumor activity compared to abatamide in multiple myeloma. Clearly, we can learn from the vast body of research surrounding abatamide. To help us achieve this potential, Duterex worked with Solaris to structure a transaction that focuses today's resources on developing 3164 by backloading development milestones. In fact, the first 3164 milestone is not due until the initiation of a registration clinical trial. With this in mind, we are focused on advancing 3164 into the clinic as a potential treatment for hematological cancers and solid tumors in 2023. During 2022, we will prepare for an IND submission, and we look forward to providing additional preclinical data updates later this year. While all this is happening, Solaris is continuing to advance the clinical development of seclidemstat, and continuing to explore opportunities to further expand the Sekla Demostat development pipeline. But before I discuss further details about Solaris' future, I would like to ask Mark Rosenbloom, Chief Financial Officer, to discuss our strong financial foundation, which is enabling all of this growth. Mark?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-